Report Highlights
The global market for circulating tumor cells (CTC) diagnostics is estimated to increase from $8.8 billion in 2021 to $15.2 billion by 2026, at a compound annual growth rate (CAGR) of 15.6% during the forecast period of 2021-2026.
Report Includes
- 24 data tables and 49 additional tables
- An up-to-date review and analysis of the global markets for circulating tumor cell (CTC) diagnostics
- Analyses of the global market trends, with data from 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the upcoming market opportunities in the CTC diagnostics industry, and areas of focus to forecast this market into various segments and sub-segments
- Evaluation and forecast the global CTC diagnostics market size, forecasted growth trends, and corresponding market share analysis by cancer type, technology, application, and region
- In-depth information concerning market drivers and challenges, latest technologies, breakthrough innovations, costs and benefits of CTC enrichment techniques, regulatory concerns, and clinical trials
- Statistical information (facts and figures) on cancer incidence and prevalence, global cancer related deaths, and new cases of cancer by type in the United States
- Review of recent industry trends, value chain analysis, competitive landscape, and COVID-19 implications within the marketplace
- Descriptive company profiles of the leading global players, including Bio-Techne Corp., Biocept Inc., Greiner Bio-One International GmbH, Precision Medicine Group LLC, Menarini Silicon Biosystems, and Qiagen N.V.
Report Scope
The scope of this study involves clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment as well as currently approved CTC tests and their markets. The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share, along with the latest trends and new developments in this area, are included to support the clinical testing market.
Based on cancer type, the market for circulating tumor cells diagnostics is segmented into breast cancer, colorectal cancer and prostate cancer.
Based on technology, the market for circulating tumor cells diagnostics is segmented into CTC enrichment and detection, CTC direct detection and CTC analysis.
Based on application, the market for circulating tumor cells diagnostics is segmented into clinical/liquid biopsy and research.
The report discusses the qualitative and quantitative factors influencing market growth. Market drivers, restraints and opportunities are discussed in the report.
This report discusses some of the major drivers and restraints in the market for circulating tumor cells diagnostics, and it surveys the competitive landscape as well as the key players’ strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also includes company profiles of major vendors that include a company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for circulating tumor cells diagnostics.
Some of the major market players discussed in the report are Qiagen N.V., Biocept Inc., Greiner Bio One International GmbH, Precision Medicine Group LLC and Menarini Silicon Biosystems. For market estimates, data have been provided for the 2020 as the base year, with forecasts for 2021 through 2026. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
Report Synopsis
Report Metrics | Details | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2020 | ||||||||||||||||
Forecast period considered | 2021-2026 | ||||||||||||||||
Base year market size | $7.6 billion | ||||||||||||||||
Market size forecast | $18.1 billion | ||||||||||||||||
Growth rate | CAGR of 15.6% from 2021 to 2026 | ||||||||||||||||
Units considered | $ Millions | ||||||||||||||||
Segments covered | Cancer Type, Technology, Application | ||||||||||||||||
Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||||||||
Countries covered | U.S., Canada, Germany, France, U.K, Spain, Italy, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Sweden, etc., Japan, China, India, Australia, New Zealand, Taiwan, South Korea, Singapore, Malaysia, Thailand, Philippines, etc. | ||||||||||||||||
Key Market Drivers |
|
||||||||||||||||
Companies studied |
|
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Bioprocess Optimization and Digital Bio-manufacturing: Global Markets (BIO170B)
- Metal-organic Frameworks: Global Markets (AVM200B)
- Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets (PHM204C)
- Global DNA Sequencing: Research, Applied and Clinical Markets (BIO045J)
- Surgical Equipment: Technologies and Global Markets (HLC154C)
Report Highlights
The global market for circulating tumor cell technology will grow from nearly $4.6 billion in 2017 to around $10.3 billion by 2022 with a compound annual growth rate (CAGR) of 17.6% for the period of 2017-2022.
Report Includes
- 118 Tables
- An overview of the global market for cancer diagnostics, based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
- Analyses of global market trends, with data from 2016, estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Discussions covering the advantages and disadvantages of CTC enrichment techniques.
- Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
- Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.
- Information about the clinical testing, prognostic, and monitoring markets for CTCs in cancer.
- Coverage of approved CTC tests and their markets, and the regulatory environment.
- Company profiles of major players across various product categories, including Cytotrack, Menarini-Silicon Biosystems And A. Menarini Diagnostics (Veridex Llc), Greiner Bio-One Gmbh, Cynvenio Biosystems Inc., Biofluidica Microtechnologies Llc and Advanced Cell Diagnostics
Report Highlights
The global market for circulating tumor cell (CTC) technology reached nearly $2.8 billion in 2012 and $3.7 billion in 2013. This market is estimated to reach nearly $8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period, 2013 to 2018.
Report Includes
- An overview of the global market for cancer diagnostics based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
- Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates for the period of 2013 to 2018.
- Discussion of the advantages and disadvantages of CTC enrichment techniques.
- Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
- Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.
Related Reports
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Flow Cytometry: Products, Technologies and Global Markets
The global market for flow cytometry products is expected to grow from $5.2 billion in 2023 to $8.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2029.
Multi-Cancer Diagnostic Tests: Global Market Outlook
This report provides an in-depth analysis of the global multi-cancer diagnostic (MCD) test market. It highlights the current and future market potential of the tests along with a detailed analysis of the drivers and challenges in the market. The report includes the company profiles of the key players with detailed information about their product portfolios and pipeline products.
Next-Generation Cancer Diagnostics: Technologies and Global Markets
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Recent Reports
Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More